Biokraft International

Report from the Annual General Meeting of Biokraft International AB (publ)

REG

Biokraft International AB (publ), reg.no 556528-4733, has today held its Annual General Meeting, at which the following main resolutions were passed.

 

Resolution on adoption of accounts, allocation of profits and discharge from liability

The Annual General Meeting adopted the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet for the financial year 2023, and resolved in accordance with the Board of Directors' proposal for allocation of profits, which means that the result for the year shall be carried forward and that no dividend shall be made for the financial year 2023. Furthermore, the Annual General Meeting granted the Board members and the CEO discharge from liability for the financial year 2023.

 

Election of Board of Directors and auditor

The Annual General Meeting resolved that the number of Board members shall be six, with two deputies, whereby Henrikki Talvitie, Håkon Welde, Miika Johansson, Kati Ylä-Autio, Jan-Harald Solstad and Christian Kronstad were re-elected as Board members and Kjell-Erik Endresen and Kristine Vergli Grant-Carlsen were re-elected as Deputy Board members. Henrikki Talvitie was re-elected as chairperson of the Board. The Annual General Meeting further resolved that no remuneration to the Board of Directors shall be paid.

 

The Annual General Meeting also resolved to re-elect the registered auditing company Öhrlings PricewaterhouseCoopers AB as the company's auditor, which intends to appoint Lars Kylberg as the auditor in charge. Fees to the auditor shall be paid according to an approved invoice within the auditor's quotation.

 

Resolution on approval of the Remuneration Report

The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, to approve the report regarding remuneration to the senior executives for 2023.

 

Issue authorisation

The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, to authorise the Board for the period up until the next annual general meeting to resolve, whether on one or several occasions and whether with or without pre-emptive rights for the shareholders, to issue new shares, warrants and convertibles, provided however that any such issue must not result in the company's share capital exceeding the company's maximum allowed share capital as set out in the articles of association. Such issue resolution may be made with or without provisions concerning non-cash consideration, set-off or other provision.

 

 

The information was submitted, through the care of the contact person below, for publication on 27 June 2024, at 13:00 CEST.

Datum 2024-06-27, kl 13:00
Källa Cision
Bifogade filer
Kopiera toppinvesterare! Med eToros innovativa CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för att använda CopyTrader-funktionen.
Copy Trading innebär inte investeringsråd. Värdet på dina investeringar kan gå upp eller ned. Ditt kapital löper risk.